Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C12H12I3N2O2.Ca |
| Molecular Weight | 1233.977 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].CN(C)C=NC1=C(I)C(CCC([O-])=O)=C(I)C=C1I.CN(C)C=NC2=C(I)C(CCC([O-])=O)=C(I)C=C2I
InChI
InChIKey=HVZGHKKROPCBDE-UHFFFAOYSA-L
InChI=1S/2C12H13I3N2O2.Ca/c2*1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19;/h2*5-6H,3-4H2,1-2H3,(H,18,19);/q;;+2/p-2
| Molecular Formula | C12H12I3N2O2 |
| Molecular Weight | 596.9493 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Iopanoic acid and ipodate salts have been used for oral cholangiography to visualize the biliary ducts. Ipodate salts have been used for the long-term treatment of Graves' disease and in hyperthyroidism. Ipodate reduced levels of T3 and T4 in the patients. Ipodate also inhibits the conversion of T4 to T3. It is not considered a first-line approach. Ipodate sodium lacks FDA approval for these uses. During investigation of mechanism of action was discovered, that binding of sodium ipodate with nuclear T3 receptors was not a prominent mechanism via which the drug attenuates T3 effects in vivo. Sodium ipodate could enhance T3 effects at the cellular level and that enhancement could not be reflected by routinely monitored serum TSH.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
250 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
IPODIC ACID blood | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1600 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
IPODIC ACID blood | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
IPODIC ACID blood | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A study of cardiac effects of thyroid hormones: evidence for amelioration of the effects of thyroxine by sodium ipodate. | 1984 Jun |
|
| The use of oral radiographic contrast agents in the management of hyperthyroidism. | 2001 Jun |
|
| Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis. | 2003 Mar |
|
| Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. | 2007 Jun |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:00:20 GMT 2023
by
admin
on
Fri Dec 15 16:00:20 GMT 2023
|
| Record UNII |
50S7W5M9ZZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1937
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
||
|
WHO-VATC |
QV08AC10
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
50S7W5M9ZZ
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | |||
|
1911
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB02751MIG
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | |||
|
214-565-8
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | |||
|
m6385
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000086430
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | |||
|
C65953
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201243
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | |||
|
14381
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | |||
|
1151-11-7
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | |||
|
DBSALT001319
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY | |||
|
DTXSID401026635
Created by
admin on Fri Dec 15 16:00:20 GMT 2023 , Edited by admin on Fri Dec 15 16:00:20 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |